EUVIMEDEUVIMED entdecken
Crossref

SGLT2 Inhibitors as Mito-Protective Agents:Delineating the Heart-Brain Axis in Neurodegeneration

Adarsh Mishra, Nisha Sharma, Ritesh Ajay Kumar Nayak, Anurag Kumar Mishra, Harshita Verma, Ajay Kumar Singh

International Journal of Drug Delivery Technology · 22.05.2026 · 16 (48s)

DOI: 10.25258/ijddt.16.48s.7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 22.05.2026. Verfasst von Adarsh Mishra und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have evolved from being simply antidiabetic agents to become multifaceted cardio-nephro-neuroprotective medications. Accumulating preclinical and clinical data indicate that they exert striking mitochondria-protective (mito-protective) effects across the heart-brain axis, a neurohumoral and metabolic bidirectional circuit connecting the heart and brain. Mitochondrial dysfunction is a common pathological hallmark of heart failure, Alzheimer disease (AD), Parkinson disease (PD) and other neurodegenerative diseases. SGLT2 inhibitors reduce oxidative stress, preserve mitochondrial membrane potential, increase mitophagy through the PINK1/Parkin and BNIP3 pathways, suppress the activation of NLRP3 inflammasome, regulate AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) signaling, and promote ketone body use as an alternative source of mitochondrial energy. By preserving cardiomyocyte function, suppressing neurohormonal activation, and penetrating into the central nervous system, they may break the vicious circle between cardiac dysfunction and accelerated neurodegenerative processes. This review consolidates mechanistic, translational and emerging clinical evidence to describe the role of SGLT2 inhibitors as mito-protective drugs along the heart-brain axis, and their potential applications in neurodegenerative conditions

Zitieren

APA

Mishra, A., Sharma, N., Nayak, R. A. K., Mishra, A. K., Verma, H., & Singh, A. K. (2026). SGLT2 Inhibitors as Mito-Protective Agents:Delineating the Heart-Brain Axis in Neurodegeneration. International Journal of Drug Delivery Technology, 16(48s). https://doi.org/10.25258/ijddt.16.48s.7

Vancouver

Mishra A, Sharma N, Nayak RAK, Mishra AK, Verma H, Singh AK. SGLT2 Inhibitors as Mito-Protective Agents:Delineating the Heart-Brain Axis in Neurodegeneration. International Journal of Drug Delivery Technology. 2026;16(48s). doi:10.25258/ijddt.16.48s.7

BibTeX
@article{Mishra2026,
  author = {Mishra, Adarsh and Sharma, Nisha and Nayak, Ritesh Ajay Kumar and Mishra, Anurag Kumar and Verma, Harshita and Singh, Ajay Kumar},
  title = {SGLT2 Inhibitors as Mito-Protective Agents:Delineating the Heart-Brain Axis in Neurodegeneration},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {48s},
  doi = {10.25258/ijddt.16.48s.7}
}
Kostenlos starten →